蔚來-SW(09866.HK)擬發行共10億美元可轉換優先債
蔚來-SW(09866.HK)公布,擬發行本金總額5億美元於2029年10月15日到期的可轉換優先債券及本金總額5億美元於2030年10月15日到期的可轉換優先債券,視乎市場情況及其他因素而定。
公司擬向債券發行中的初始購買者授予可自債券發行日期起計30日內行使的選擇權,以增購最多本金總額7,500萬美元的2029年債券及增購最多本金總額7,500萬美元的2030年債券。
一經發行,債券將為蔚來的優先、無抵押債務。公司計劃將部分債券發行所得款項淨額用於回購部分現有債務證券,餘下所得款項淨額主要用於進一步加強資產負債表狀況以及一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.